Moderna's voluntary withdrawal of the filing stems from the FDA's request for vaccine efficacy data from a phase III study on ...

After dropping by 15.74% to close at $1,707.94 yesterday, the stock could continue to pull back today. Shares fell after ...

This was the stock's second consecutive day of losses.

The FDA has granted full approval for Novavax's COVID-19 vaccine, but with restrictions. Discover the details now.

BofA analyst Alec Stranahan reiterated a Hold rating on Novavax, Inc. (NASDAQ:NVAX) stock, setting a price target of $10. The approval of Nuvaxovid for use in older and high-risk adults will generate ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years ...

Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

The approval marks a significant milestone for Novavax Inc. (NASDAQ:NVAX), aligning with the changing regulatory landscape ...

JPMorgan analyst Eric Joseph reaffirmed an Underweight rating for Novavax Inc. (NASDAQ:NVAX) with a price target of $7. This ...

Live Updates Live Coverage Has Ended Markets Turn Positive 1:37 pm by The stock market has managed to crawl its way back ...

Live Updates Live Coverage Updates appear automatically as they are published. Retail Earnings on Deck 10:28 am by With the ...